Esperion Therapeutics Sees Surge in Call Options Trading Activity
On November 6, 2023, trading activity in Esperion Therapeutics, Inc. (NASDAQ:ESPR) attracted attention as traders engaged in an unusually high volume of call options. A total of 4,601 call options were purchased, marking an increase of approximately 48% over the average volume of 3,108 call options. This surge suggests heightened investor interest in the company’s stock.
The stock responded positively during mid-day trading, rising by 15%, or $0.48, to reach $3.65. In total, 9,533,113 shares changed hands, significantly exceeding the average volume of 5,452,090 shares. With a market capitalization of $871.37 million, Esperion’s stock is characterized by a price-to-earnings ratio of -7.33 and a beta of 0.92. Over the past year, the stock has experienced a low of $0.69 and a high of $3.94, with its fifty-day simple moving average currently at $2.80 and a two-hundred-day moving average at $1.93.
Recent Earnings Report Highlights
Esperion Therapeutics released its latest earnings results on November 6, 2023. The biopharmaceutical company reported a loss of $0.16 earnings per share (EPS), falling short of analysts’ consensus expectations of $0.09 by $0.07. Despite this, the company generated revenue of $87.31 million for the quarter, surpassing the consensus estimate of $78.33 million. Analysts project that Esperion will post a loss of $0.29 EPS for the current fiscal year.
Institutional Investment Activity
Recent movements among institutional investors reflect a growing interest in Esperion. DHJJ Financial Advisors Ltd. increased its holdings by 209.2% in the third quarter, now owning 9,430 shares valued at approximately $25,000. Other notable transactions include Vanguard Personalized Indexing Management LLC, which acquired a stake worth around $29,000, and CWM LLC, which grew its holdings by 46.5%, now owning 19,674 shares valued at $52,000.
Notably, approximately 47.39% of Esperion’s stock is owned by institutional investors and hedge funds. These investments indicate a significant level of confidence in the company’s future prospects.
Esperion Therapeutics, Inc. specializes in developing and commercializing treatments for patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are oral, once-daily medications aimed at patients requiring additional LDL-C lowering.
As market dynamics continue to evolve, investors will be watching closely to see how Esperion navigates its upcoming challenges and opportunities in the biopharmaceutical sector.
